SELLAS Life Sciences (SLS) Change in Cash (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Change in Cash data on file, last reported at $35.3 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $35.3 million, up 143.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $78.7 million (up 688.42% YoY), and the FY2025 annual result was $57.9 million, up 409.92% from the prior year.
• Change in Cash rose to $35.3 million in Q1 2026 per SLS's latest filing, from $27.5 million in the prior quarter.
• Over five years, Change in Cash peaked at $35.3 million in Q1 2026 and troughed at -$10.1 million in Q2 2023.
• A 5-year average of $5.0 million and a median of -$1.4 million in 2023 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2024: Change in Cash surged 575.96% in 2022, then plunged 396.53% in 2024.
• A 5-year view of Change in Cash shows it stood at -$4.2 million in 2022, then soared by 65.92% to -$1.4 million in 2023, then slumped by 396.53% to -$7.1 million in 2024, then surged by 484.51% to $27.5 million in 2025, then grew by 28.5% to $35.3 million in 2026.
• Business Quant data shows SLS's Change in Cash at $35.3 million in Q1 2026, $27.5 million in Q4 2025, and $19.0 million in Q3 2025.